AI Research Insights

The ALPK1 clinical studies are early but advancing, led by Drug Farm with dual agonist and inhibitor programs targeting inflammatory, infectious, and rare genetic diseases.

Recent advances in Nipah virus immunity and pathogenesis reveal key immunological gaps limiting rational vaccine and therapeutic design.

In 2025, TNBC was redefined by first-line TROP2 ADC breakthroughs, delivering major PFS/OS results and accelerating regulatory.

This review outlines key clinical breakthroughs, regulatory milestones, and next-generation innovations shaping CAR-T therapy in hematologic malignancies from 2021–2026.